Sarepta Therapeutics (NASDAQ:SRPT) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report published on Monday, Benzinga reports. The brokerage currently has a $182.00 price target on the biotechnology company’s stock.

Several other equities research analysts also recently weighed in on the stock. UBS Group increased their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Citigroup decreased their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Barclays cut their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and decreased their price target for the stock from $185.00 to $179.00 in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $152.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, September 20th. Two analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $182.95.

Sarepta Therapeutics Stock Up 1.6 %

Shares of NASDAQ SRPT opened at $132.02 on Monday. The company has a current ratio of 3.90, a quick ratio of 3.19 and a debt-to-equity ratio of 1.05. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25. The firm’s 50-day moving average price is $128.78 and its 200-day moving average price is $132.40. The stock has a market capitalization of $12.48 billion, a price-to-earnings ratio of 1,200.18 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period last year, the company earned ($0.27) EPS. On average, equities research analysts anticipate that Sarepta Therapeutics will post 1.45 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers acquired 37,038 shares of the stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC increased its stake in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. raised its stake in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after acquiring an additional 317,277 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in Sarepta Therapeutics by 2,257.8% during the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after acquiring an additional 230,300 shares during the period. Rhumbline Advisers grew its stake in Sarepta Therapeutics by 146.3% during the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after purchasing an additional 160,942 shares during the last quarter. Finally, Blair William & Co. IL increased its holdings in shares of Sarepta Therapeutics by 303.7% in the second quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after purchasing an additional 131,112 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.